Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes

Robert J. Chilton; Kathleen M. Dungan; Jay H. Shubrook; Guillermo E. Umpierrez

doi:10.1016/j.pcd.2019.09.008

Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes

Robert J. Chilton, Kathleen M. Dungan, Jay H. Shubrook, Guillermo E. Umpierrez

Division of Cardiology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.

Original language	English (US)
Pages (from-to)	193-212
Number of pages	20
Journal	Primary Care Diabetes
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.pcd.2019.09.008
State	Published - Jun 2020

Keywords

Antihyperglycemic
Cardiovascular outcome trials
Cardiovascular risk
Type 2 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics

Access to Document

10.1016/j.pcd.2019.09.008

Fingerprint Dive into the research topics of 'Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes'. Together they form a unique fingerprint.

Cite this

@article{1f924af9171e45b7a0217ca10a54c1e7,

title = "Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes",

abstract = "Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.",

keywords = "Antihyperglycemic, Cardiovascular outcome trials, Cardiovascular risk, Type 2 diabetes",

author = "Chilton, {Robert J.} and Dungan, {Kathleen M.} and Shubrook, {Jay H.} and Umpierrez, {Guillermo E.}",

note = "Funding Information: RJC has been a consultant/advisor to AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eli Lilly & Co, Novo Nordisk, Takeda, Medtronic, and Pfizer. GEU is partly supported by research grants from the National Institute of Health and National Center for Advancing Translational Science (UL1 RR025008), and 1P30DK111024-01 from the National Center for Research Resources. GEU has received unrestricted research support for inpatient studies (to Emory University) from Dexcom, Novo Nordisk, and Sanofi. KMD discloses research support from Sanofi Aventis, Novo Nordisk, Glaxo Smith Kline, AstraZeneca, consulting activities with Eli Lilly & Co, Sanofi Aventis, and MannKind. JHS serves as an advisor to Eli Lilly & Co, Novo Nordisk and Intarcia. ",

year = "2020",

month = jun,

doi = "10.1016/j.pcd.2019.09.008",

language = "English (US)",

volume = "14",

pages = "193--212",

journal = "Primary Care Diabetes",

issn = "1751-9918",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes

AU - Chilton, Robert J.

AU - Dungan, Kathleen M.

AU - Shubrook, Jay H.

AU - Umpierrez, Guillermo E.

N1 - Funding Information: RJC has been a consultant/advisor to AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eli Lilly & Co, Novo Nordisk, Takeda, Medtronic, and Pfizer. GEU is partly supported by research grants from the National Institute of Health and National Center for Advancing Translational Science (UL1 RR025008), and 1P30DK111024-01 from the National Center for Research Resources. GEU has received unrestricted research support for inpatient studies (to Emory University) from Dexcom, Novo Nordisk, and Sanofi. KMD discloses research support from Sanofi Aventis, Novo Nordisk, Glaxo Smith Kline, AstraZeneca, consulting activities with Eli Lilly & Co, Sanofi Aventis, and MannKind. JHS serves as an advisor to Eli Lilly & Co, Novo Nordisk and Intarcia.

PY - 2020/6

Y1 - 2020/6

N2 - Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.

AB - Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.

KW - Antihyperglycemic

KW - Cardiovascular outcome trials

KW - Cardiovascular risk

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85075467161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075467161&partnerID=8YFLogxK

U2 - 10.1016/j.pcd.2019.09.008

DO - 10.1016/j.pcd.2019.09.008

M3 - Review article

C2 - 31704161

AN - SCOPUS:85075467161

VL - 14

SP - 193

EP - 212

JO - Primary Care Diabetes

JF - Primary Care Diabetes

SN - 1751-9918

IS - 3

ER -